Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, First-in-human, 6-Part Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Subjects

Trial Profile

A Randomized, Double-blind, Placebo-controlled, First-in-human, 6-Part Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Dec 2018

At a glance

  • Drugs JNJ-64417184 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Alios BioPharma
  • Most Recent Events

    • 16 Oct 2018 Planned End Date changed from 28 Dec 2018 to 30 Jun 2019.
    • 16 Oct 2018 Planned primary completion date changed from 28 Dec 2018 to 30 Jun 2019.
    • 11 Jun 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top